Free-to-Use eLearning Modules
Applied Clinical Trials
Apart from training and certifying individual EC members, the Dutch Central Committee on Research involving Human Subjects (CCMO) recently added training of investigators to its repertoire.
Apart from training and certifying individual EC members, the Dutch Central Committee on Research involving Human Subjects (CCMO) recently added training of investigators to its repertoire.
On December 3, 2012, at the Academic Medical Center Amsterdam, Prof. dr. Marcel Levi opened the eLearning website Onderzoekswijs.nl. "Clinical Research in our country is still standing strong, as compared to other EU countries. The number of trials taking place in the Netherlands this year is even a bit higher as compared to last year," Levi said. Of all trials performed in the Netherlands, more than 40% are categorized as "investigator-initiated," a number which has remained quite stable over the last few years.
The free-to-use modules, that were designed on the basis of frequently asked questions from the field, offer no examination. However, after the instructions, a user may test his/her knowledge gained by answering a few questions, with direct feedback. Currently six themes are covered:
- Do I need to submit my research trial?
- Submitting a trial.
- Multi-center trial.
- Performing a trial.
- SAEs and SUSARs.
- Other applicable laws and regulations.
Four of the six start off with a video fragment. More modules may be added. In principle, the eLearning is intended for those interested/involved in investigator-initiated trials. However, any investigator may benefit from its contents.
CCMO anticipates the eLearning modules will soon be used in the compulsory training by all eight Dutch University Medical Centers.
The website's slogan is "Test and Increase Your Knowledge" with the language used in the eLearning modules being Dutch. Further information can be obtained from ccmo@ccmo.nl.
—Edgar Smeets
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
